ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable pancreatic cancer patients in Ph 2 AMPLIFY-7P Trial September 23, 2025
Avenzo Therapeutics Announces $60 Million Series B Financing to support pipeline advancement of oncology drug candidates September 23, 2025
First patient dosed in Ph 1/2 Dose Escalation & Expansion Trial of CP-383 in Advanced Solid Tumors September 23, 2025
Extended Survival Achieved in Low PD-L1 Cohort in VERSATILE-002 Trial of PDS0101 (Versamune® HPV) + Keytruda in patients with HPV16-positive 1L R/M HNSCC September 23, 2025
IND application amended with updated OS data from Ph 2 Actuate-1801 Part 3B trial of elraglusib + GnP versus GnP alone in 1L metastatic pancreatic cancer September 23, 2025
Arvinas and Pfizer plan to jointly select third party for the out-licensing and commercialization of vepdegestrant September 23, 2025
Tinostamustine included in Ph 2/3 GBM AGILE adaptive clinical trial for GBM patients September 23, 2025
100% MRD negativity seen in Ph 2 MajesTEC-5 study of TECVAYLI & DARZALEX FASPRO induction in transplant-eligible 1L multiple myeloma September 23, 2025
FDA Approves SC KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection Across Most Solid Tumor Indications for KEYTRUDA September 23, 2025
Pidnarulex (CX-5461) + Cemiplimab (Libtayo®) combo to be tested in Ph 1/2 clinical trial for MSS CRC patients September 23, 2025
SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer September 23, 2025
Immutep Announces Research Collaboration with the George Washington University Cancer Center to Evaluate Neoadjuvant Efti September 23, 2025
Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked ADC September 23, 2025
Initial patients dosed in multiple cohorts of Ph 1 dose-expansion study of KTX-1001, mezigdomide, and SoC combo in t(4;14) multiple myeloma September 23, 2025
First Patient Dosed in Ph 2 Study of AK130 + Ivonescimab for Advanced Pancreatic Cancer September 23, 2025
LP-184 Ph 1a Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors September 23, 2025
New Ph 2 Data for Stenoparib/2X-121 Showed Landmark Median OS Surpassing 25 Months September 23, 2025
